NETRIS PHARMA SAS
Desconocido
BonePainIII: Identifying mechanisms and novel treatments of bone pain – closing the gap to the clinic.
NETRIS PHARMA SAS
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2022-DN-01
Musculoskeletal pain from diseases such as arthritis and cancer in the bone affects the quality of life of millions and is a major societal...
2023-07-14 - 2027-12-31 | Financiado
2023-07-14 - 2027-12-31 | Financiado
ImmunoNet: Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1
NETRIS PHARMA SAS
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2021-ACCELERATOROPEN-01
Immune Checkpoint Inhibitors (ICPIs) have recently revolutionized the treatment and management of cancer. Yet, progress recorded and impact...
2022-08-31 - 2025-12-31 | Financiado
2022-08-31 - 2025-12-31 | Financiado
HERMIONE-2MAN: First in Man Novel Anticancer Therapeutic based on Dependence Receptors Concept
NETRIS PHARMA SAS
participó en un
FP7:
It is usually assumed that transmembrane receptors are inactive unless bound by their respective ligand. Against this dogma, the CLB propose...
Financiado
Financiado
* No se disponen de datos de la empresa actual.